Linked Life Data

20727512

Source:http://linkedlifedata.com/resource/pubmed/id/20727512

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2010-8-23
pubmed:abstractText
Anticoagulation therapy is commonly required in patients with chronic kidney disease for treatment or prevention of thromboembolic disorders. Anticoagulant management plans can involve use of a single agent, or in some cases, a combination of agents to meet both short- and long-term goals. Systemic anticoagulation in the setting of renal insufficiency poses unique challenges secondary to renal failure-associated hypercoagulable conditions and increased risks for bleeding. Evidence supporting dosing regimens and monitoring approaches in the setting of severe renal impairment or hemodialysis is limited because this population is typically excluded in clinical trials. This review explores concepts of systemic anticoagulation in the chronic kidney disease setting with warfarin, unfractionated heparin, low-molecular-weight heparin, fondaparinux, direct thrombin inhibitors, and anticoagulants in advanced stages of development. Potential strategies for anticoagulant reversal are also briefly described.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1548-5609
pubmed:author
pubmed:copyrightInfo
2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
420-7
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Systemic anticoagulation considerations in chronic kidney disease.
pubmed:affiliation
University of California, Davis Medical Center, Sacramento, 95817-2201, USA. william.dager@ucdmc.ucdavis.edu
pubmed:publicationType
Journal Article, Review